Purpura fulminans: MRSA sepsis compounded by diclofenac

Authors

  • Mahym Mansoor Department of Dermatology, KEMU/ Mayo Hospital, Lahore
  • Wajieha Saeed Department of Dermatology, KEMU/ Mayo Hospital, Lahore
  • Faria Altaf Department of Dermatology, SIMS/ Services Hospital, Lahore
  • Ijaz Hussain Department of Dermatology, KEMU/ Mayo Hospital, Lahore
  • Farwa Nasir Khan Department of Dermatology, THQ Safdarabad

DOI:

https://doi.org/10.66344/jpad.33.4.2023.2589

Keywords:

Purpura fulminans, diclofenac, MRSA

Abstract

Purpura fulminans is a rare, albeit a life-threatening emergency which has been reportedly triggered by infections, congenital disorders of protein C or S deficiencies, as well as drugs. Here we report a case of a previously healthy 17 year old male who developed purpura fulminans after fever, sore throat and then getting injection diclofenac. Blood cultures grew Staph. aureus. This case is the first to report two causative etiologies in a single patient.     Key words: purpura fulminans, MRSA, diclofenac.

References

Contou D, Urbina T, de Prost N. Understanding purpura fulminans in adult patients. Intensive care medicine. 2022 Jan;48(1):106-10.

Perera TB, Murphy-Lavoie HM. Purpura Fulminans. In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2021. PMID: 30422460.

Lowry J, Noel E. A Rare Cause of a Rare Disorder: E. coli-Induced Purpura Fulminans Secondary to Urinary Tract Infection. Case Reports in Critical Care. 2022 Apr 6;2022.

de Villa AR, Charles K, Okonoboh P. A Rare Case of Purpura Fulminans in the Setting of Klebsiella pneumoniae Bacteremia. Cureus. 2022 Mar 7;14(3).

Zhitny VP, Lyons M, Perloff A, Menezes J, Pistorio A, Baynosa R. COVID-19 association with purpura fulminans: report of a life threatening complication in a fully vaccinated patient. Journal of Surgical Case Reports. 2022 Mar;2022(3):rjac095

Tang X, Zhang Z, Yang H, Xiao J, Wen X, Dou Y, Yu J, Hu Y. Clinical and genetic features of Chinese pediatric patients with severe congenital protein C deficiency who first presented with purpura fulminans: A case series study and literature review. Thrombosis research. 2022 Jan 3.

CN K. Neonatal Purpura fulminans due to congenital protein C deficiency: case series. University Journal of Medicine and Medical Specialities. 2021 Sep 26;7(2).

Kosaraju N, Korrapati V, Thomas A, James BR. Adult purpura fulminans associated with non-steroidal anti-inflammatory drug use. J Postgrad Med. 2011 Apr-Jun;57(2):145-6.

Russom M, Fitsum Y, Abraham A, Savage RL. Diclofenac and the Risk of Rhabdomyolysis: Analysis of Publications and the WHO Global Pharmacovigilance Database. Drugs Real World Outcomes. 2021 Sep; 8(3): 263–75.

Alves F, Brites MM, Coutinho I. Purpura Fulminans in a 20-Year-Old Female. Journal of the Portuguese Society of Dermatology and Venereology. 2021 Dec 27;79(4):369-71.

Downloads

Published

2023-10-12

How to Cite

1.
Mansoor M, Saeed W, Altaf F, Hussain I, Khan FN. Purpura fulminans: MRSA sepsis compounded by diclofenac. J Pak Assoc Dermatol [Internet]. 2023Oct.12 [cited 2026Apr.22];33(4):1780-2. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/2589

Issue

Vol. 33 No. 4 (2023): October-December

Section

Case Reports

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.